British journal of haematology
Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.
Jin-Hua Wang, Qing Yang, Shao-Qin Duan, Li Yang, Yan Zhou, Chun-Lian Fang, Zu-Gang Xiao, Chun-Hui Yang, Yong-Chao Xiong, Xin Tian, Ti-Long Huang, Xian-Wen Zhang
Published: 202610.1111/bjh.70309
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder that occurs in children and adults, and it is characterized by a reduced platelet count. Hetrombopag, a novel thrombopoietin receptor agonist (TPO-RA) for second-line ITP treatment, lacks thorou…
Preview only. Read the full abstract at the source